Profile data is unavailable for this security.
About the company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
- Revenue in USD (TTM)79.60m
- Net income in USD1.20m
- Incorporated1988
- Employees96.00
- LocationDelcath Systems Inc566 Queensbury AvenueQUEENSBURY 12804United StatesUSA
- Phone+1 (518) 743-8892
- Fax+1 (212) 489-2102
- Websitehttps://delcath.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simulations Plus Inc | 78.68m | -64.25m | 247.60m | 212.00 | -- | 1.95 | -- | 3.15 | -3.20 | -3.20 | 3.90 | 6.31 | 0.4701 | -- | 4.28 | 371,113.20 | -38.39 | -2.50 | -40.84 | -2.65 | 59.60 | 69.96 | -81.66 | -7.29 | -- | -- | 0.00 | -- | 13.09 | 13.74 | -750.17 | -- | 7.57 | -24.21 |
| Applied Energetics Inc | 1.15m | -13.02m | 256.97m | 21.00 | -- | -- | -- | 222.85 | -0.0599 | -0.0599 | 0.0053 | -0.0033 | 0.3065 | -- | 7.70 | 54,908.57 | -345.27 | -139.08 | -454.84 | -208.36 | 58.58 | 60.61 | -1,126.59 | -473.16 | -- | -- | -- | -- | -7.78 | -- | -24.71 | -- | 51.42 | -- |
| Quanterix Corp | 130.20m | -95.66m | 268.12m | 471.00 | -- | 0.8519 | -- | 2.06 | -2.33 | -2.33 | 3.21 | 6.74 | 0.3045 | 1.44 | 4.06 | 276,439.50 | -22.37 | -13.18 | -25.81 | -14.53 | 51.53 | 56.14 | -73.47 | -45.09 | 2.31 | -- | 0.0029 | -- | 12.30 | 19.36 | -35.89 | -- | -20.86 | -- |
| Shoulder Innovations Inc | 41.63m | -34.45m | 269.06m | 61.00 | -- | 1.82 | -- | 6.46 | -1.91 | -1.91 | 2.24 | 7.18 | -- | -- | -- | -- | -- | -- | -- | -- | 76.67 | -- | -82.75 | -- | 9.80 | -- | 0.0913 | -- | 64.07 | -- | -50.85 | -- | -- | -- |
| Sight Sciences Inc | 76.05m | -46.11m | 283.39m | 216.00 | -- | 4.37 | -- | 3.73 | -0.8955 | -0.8955 | 1.47 | 1.23 | 0.5854 | 1.42 | 6.71 | 352,092.60 | -35.49 | -35.50 | -39.37 | -38.53 | 86.83 | 82.63 | -60.63 | -94.20 | 8.93 | -76.38 | 0.384 | -- | -1.47 | 27.89 | 7.27 | -- | -10.54 | -- |
| Carlsmed Inc | -100.00bn | -100.00bn | 291.19m | 100.00 | -- | 2.73 | -- | -- | -- | -- | -- | 4.01 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 11.91 | -- | 0.1265 | -- | 97.16 | -- | -31.49 | -- | -- | -- |
| Trubridge Inc | 349.88m | 5.42m | 292.68m | 3.20k | 52.57 | 1.62 | 9.13 | 0.8365 | 0.3709 | 0.3709 | 24.23 | 12.02 | 0.8737 | 257.08 | 6.17 | 109,338.40 | 1.39 | -0.9107 | 1.60 | -1.03 | 53.16 | 50.13 | 1.59 | -1.14 | 1.90 | 2.40 | 0.4768 | -- | 0.946 | 4.52 | 56.05 | -- | 61.10 | -- |
| Owlet Inc | 99.64m | -42.45m | 301.46m | 80.00 | -- | -- | -- | 3.03 | -2.75 | -2.75 | 6.08 | -2.34 | 1.52 | 3.80 | 4.36 | 1,245,500.00 | -60.37 | -64.44 | -244.32 | -331.11 | 52.06 | 44.29 | -39.68 | -58.72 | 0.9074 | -2.48 | -- | -- | 44.52 | 9.40 | 54.08 | -- | -17.23 | -- |
| Senseonics Holdings Inc | 29.30m | -63.77m | 306.85m | 117.00 | -- | 3.92 | -- | 10.47 | -1.65 | -1.65 | 0.7565 | 1.92 | 0.248 | 3.62 | 5.22 | 250,410.30 | -53.98 | -71.11 | -70.98 | -94.75 | 41.11 | -14.81 | -217.65 | -594.09 | 5.93 | -29.18 | 0.3109 | -- | 0.3662 | 1.08 | -30.18 | -- | 16.46 | -- |
| Evolent Health Inc | 2.05bn | -180.89m | 311.37m | 4.50k | -- | 0.3697 | -- | 0.1516 | -1.57 | -1.57 | 17.85 | 7.55 | 0.829 | -- | 5.17 | 456,456.00 | -5.17 | -5.93 | -6.41 | -8.00 | 18.42 | 21.07 | -6.24 | -7.16 | -- | 0.189 | 0.5572 | -- | 30.09 | 30.04 | 34.31 | -- | -6.87 | -- |
| Delcath Systems Inc | 79.60m | 1.20m | 328.77m | 96.00 | 1,070.12 | 2.86 | 235.85 | 4.13 | 0.0087 | 0.0087 | 2.10 | 3.25 | 1.02 | 1.26 | 7.70 | 829,197.90 | 1.54 | -94.54 | 1.90 | -143.97 | 86.29 | 81.31 | 1.50 | -339.85 | 13.71 | -- | 0.00 | -- | 1,701.70 | 88.10 | 44.66 | -- | 87.69 | -- |
| Rxsight Inc | 142.09m | -35.73m | 330.58m | 498.00 | -- | 1.20 | -- | 2.33 | -0.8782 | -0.8782 | 3.50 | 6.72 | 0.4591 | 1.40 | 5.74 | 285,313.30 | -11.54 | -19.50 | -12.45 | -21.50 | 74.98 | 57.17 | -25.15 | -52.00 | 11.44 | -- | 0.0004 | -- | 57.09 | 128.61 | 43.52 | -- | 5.89 | -- |
| Clearpoint Neuro Inc | 34.33m | -23.14m | 403.09m | 115.00 | -- | 24.27 | -- | 11.74 | -0.8264 | -0.8264 | 1.23 | 0.5584 | 0.6829 | 1.95 | 7.52 | 298,539.10 | -46.03 | -35.94 | -54.48 | -41.48 | 61.31 | 63.49 | -67.40 | -74.87 | 5.56 | -92.37 | 0.6479 | -- | 31.04 | 22.85 | 14.37 | -- | 11.41 | -- |
| Myriad Genetics Inc | 825.30m | -400.50m | 418.53m | 2.70k | -- | 1.12 | -- | 0.5071 | -4.34 | -4.34 | 8.97 | 4.00 | 0.9122 | 8.46 | 6.77 | 305,666.70 | -44.27 | -- | -53.15 | -- | 70.36 | -- | -48.53 | -- | 2.12 | -14.93 | 0.2427 | -- | 11.21 | -- | 51.65 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Delcath Systems Inc's reporting currency: US Dollar USD
28.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 31 Dec 2025 | 3.30m | 9.48% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.61m | 4.62% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.47m | 4.23% |
| Geode Capital Management LLCas of 31 Dec 2025 | 682.83k | 1.96% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 608.01k | 1.75% |
| Divisadero Street Capital Management LPas of 30 Sep 2025 | 476.16k | 1.37% |
| Propel Bio Management LLCas of 31 Dec 2025 | 438.51k | 1.26% |
| Ikarian Capital LLCas of 30 Sep 2025 | 431.25k | 1.24% |
| ExodusPoint Capital Management LPas of 30 Sep 2025 | 379.58k | 1.09% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 361.60k | 1.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
